Lung Cancer Clinical Trial

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

Summary

Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adults, 18 years of age or older, at the time of diagnosis with any solid tumor.
Confirmed NRG1 gene fusion in any solid tumor.
Initiated afatinib or other systemic therapy (in any line of therapy) for treatment of a solid tumor with NRG1 gene fusion on or after 01/01/2017 through 03/31/2020.
Followed up for ≥3 months after initiation of afatinib or other systemic therapy (unless deceased prior to 3 months of follow-up).

Exclusion Criteria:

- Treatment with any Tyrosine kinase inhibitor (TKI)/ErbB-directed therapy other than afatinib

Study is for people with:

Lung Cancer

Estimated Enrollment:

110

Study ID:

NCT04750824

Recruitment Status:

Completed

Sponsor:

Boehringer Ingelheim

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Cardinal Health
Dublin Ohio, 43017, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

110

Study ID:

NCT04750824

Recruitment Status:

Completed

Sponsor:


Boehringer Ingelheim

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider